“…Two particular HPV species, alpha-7 (HPV 18, 39, 45, 59, 68 and 70) and alpha-9 (HPV 16, 31, 33, 35, 52, 58 and 67), have been found in over 80 % of all patients with cervical cancer. HPV infection status is postulated to directly influence the likelihood of response to chemoradiation therapy in other malignancies such as head and neck cancers [23,24]. In our study, the likelihood of metabolic response was not different between the higher-risk HPV group (71 % CMR) and the lower-risk HPV group (75 % CMR, p=0.83), and there was no significant difference in in-field metabolic control (p=0.29).…”